Immunohistochemical Expression of the Sodium/Iodide Symporter in Patients with Primary Lung Cancer
이현욱, 노미숙, 강도영, 양두경, 이경은, 최필조, 김기남,
소속 상세정보
이현욱 ( Lee Hyoun-Wook )
동아대학교 의과대학 병리학교실
노미숙 ( Roh Mee-Sook )
동아대학교 의과대학 병리학교실
강도영 ( Kang Do-Young )
동아대학교 의과대학 핵의학교실
양두경 ( Yang Doo-Kyung )
동아대학교 의과대학 내과학교실
이경은 ( Lee Kyung-Eun )
동아대학교 암분자치료연구센터
최필조 ( Choi Phil-Jo )
동아대학교 의과대학 흉부외과학교실
김기남 ( Kim Ki-Nam )
동아대학교 의과대학 진단방사선학교실
KMID : 0357920060400020081
Abstract
Background: The sodium/iodide symporter (NIS) is a membrane glycoprotein that facilitates the uptake of iodine by thyroid follicular cells. Although the use of radioiodide is essential for the diagnosis and treatment of thyroid diseases, few studies have been conducted to investigate the use of NIS-mediated radioiodide accumulation in lung cancer. We evaluated the expression of NIS by immunohistochemistry in order to examine the diagnostic or therapeutic feasibility of using radioiodide in the treatment of primary lung cancer.
Methods: Immunohistochemistry for NIS was performed in 139 lung cancers. The expression pattern of NIS was compared with the clinicopathological characteristics of the tumors.
Results: NIS immunoreactivity was detected in 75 (54.0%) of the 139 cases. Twenty-three (37.7%) of the 61 squamous cell carcinomas, 49 (76.6%) of the 64 adenocarcinomas, 2 (40.0%) of the 5 small cell carcinomas, and 3 (33.3%) of the 9 other carcinomas showed positive NIS immunoreactivity. The expression of NIS was significantly associated with the histologic type (p<0.001), but it did not correlate with tumor size, lymphovascular invasion or lymph node metastasis.
Conclusions: The presence of NIS was detected in lung cancer tissue using immunohistochemistry. Lung cancer potentially could be targeted with radioiodide for both diagnosis and treatment, especially in cases of adenocarcinoma.
키워드
Lung cancer;Sodium iodide symporter;Immunohistochemistry
원문 및 링크아웃 정보
등재저널 정보